Dialysate calcium, alfacalcidol, and clinical outcomes: A post-hoc analysis of the J-DAVID trial.
The selection of dialysate calcium concentration (D-Ca) is still controversial among chronic hemodialysis (HD) regimens. We examined the trajectories of CKD MBD parameters among the J-DAVID trial participants to see the effect of D-Ca and alfacalcidol. The trial was an open-label randomized clinical...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2022-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0273195 |
| _version_ | 1798000741568217088 |
|---|---|
| author | Kunitoshi Iseki Daijiro Kabata Tetsuo Shoji Masaaki Inaba Masanori Emoto Katsuhito Mori Tomoaki Morioka Shinya Nakatani Ayumi Shintani |
| author_facet | Kunitoshi Iseki Daijiro Kabata Tetsuo Shoji Masaaki Inaba Masanori Emoto Katsuhito Mori Tomoaki Morioka Shinya Nakatani Ayumi Shintani |
| author_sort | Kunitoshi Iseki |
| collection | DOAJ |
| description | The selection of dialysate calcium concentration (D-Ca) is still controversial among chronic hemodialysis (HD) regimens. We examined the trajectories of CKD MBD parameters among the J-DAVID trial participants to see the effect of D-Ca and alfacalcidol. The trial was an open-label randomized clinical trial including 976 HD patients with intact PTH of 180 pg/mL or lower which compared the users of vitamin D receptor activator (oral alfacalcidol) and non-users over a median of 4 years. The main D-Ca used at baseline were 3.0 mEq/L in 70% and 2.5 mEq/L in 25%, respectively. The primary endpoint was the composite of fatal and non-fatal cardiovascular events and the secondary endpoint was all-cause mortality. Multivariable Cox proportional hazard regression analyses in which D-Ca was included as a possible effect modifier and serum laboratory data as time-varying covariates showed no significant effect modification for composite cardiovascular events or all-cause mortality. This post hoc analysis showed that the effects of alfacalcidol on cardiovascular outcomes were not significantly modified by D-Ca. |
| first_indexed | 2024-04-11T11:25:12Z |
| format | Article |
| id | doaj.art-caf04cd7cb894df2892c4ad18ac6876b |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-11T11:25:12Z |
| publishDate | 2022-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-caf04cd7cb894df2892c4ad18ac6876b2022-12-22T04:26:18ZengPublic Library of Science (PLoS)PLoS ONE1932-62032022-01-01179e027319510.1371/journal.pone.0273195Dialysate calcium, alfacalcidol, and clinical outcomes: A post-hoc analysis of the J-DAVID trial.Kunitoshi IsekiDaijiro KabataTetsuo ShojiMasaaki InabaMasanori EmotoKatsuhito MoriTomoaki MoriokaShinya NakataniAyumi ShintaniThe selection of dialysate calcium concentration (D-Ca) is still controversial among chronic hemodialysis (HD) regimens. We examined the trajectories of CKD MBD parameters among the J-DAVID trial participants to see the effect of D-Ca and alfacalcidol. The trial was an open-label randomized clinical trial including 976 HD patients with intact PTH of 180 pg/mL or lower which compared the users of vitamin D receptor activator (oral alfacalcidol) and non-users over a median of 4 years. The main D-Ca used at baseline were 3.0 mEq/L in 70% and 2.5 mEq/L in 25%, respectively. The primary endpoint was the composite of fatal and non-fatal cardiovascular events and the secondary endpoint was all-cause mortality. Multivariable Cox proportional hazard regression analyses in which D-Ca was included as a possible effect modifier and serum laboratory data as time-varying covariates showed no significant effect modification for composite cardiovascular events or all-cause mortality. This post hoc analysis showed that the effects of alfacalcidol on cardiovascular outcomes were not significantly modified by D-Ca.https://doi.org/10.1371/journal.pone.0273195 |
| spellingShingle | Kunitoshi Iseki Daijiro Kabata Tetsuo Shoji Masaaki Inaba Masanori Emoto Katsuhito Mori Tomoaki Morioka Shinya Nakatani Ayumi Shintani Dialysate calcium, alfacalcidol, and clinical outcomes: A post-hoc analysis of the J-DAVID trial. PLoS ONE |
| title | Dialysate calcium, alfacalcidol, and clinical outcomes: A post-hoc analysis of the J-DAVID trial. |
| title_full | Dialysate calcium, alfacalcidol, and clinical outcomes: A post-hoc analysis of the J-DAVID trial. |
| title_fullStr | Dialysate calcium, alfacalcidol, and clinical outcomes: A post-hoc analysis of the J-DAVID trial. |
| title_full_unstemmed | Dialysate calcium, alfacalcidol, and clinical outcomes: A post-hoc analysis of the J-DAVID trial. |
| title_short | Dialysate calcium, alfacalcidol, and clinical outcomes: A post-hoc analysis of the J-DAVID trial. |
| title_sort | dialysate calcium alfacalcidol and clinical outcomes a post hoc analysis of the j david trial |
| url | https://doi.org/10.1371/journal.pone.0273195 |
| work_keys_str_mv | AT kunitoshiiseki dialysatecalciumalfacalcidolandclinicaloutcomesaposthocanalysisofthejdavidtrial AT daijirokabata dialysatecalciumalfacalcidolandclinicaloutcomesaposthocanalysisofthejdavidtrial AT tetsuoshoji dialysatecalciumalfacalcidolandclinicaloutcomesaposthocanalysisofthejdavidtrial AT masaakiinaba dialysatecalciumalfacalcidolandclinicaloutcomesaposthocanalysisofthejdavidtrial AT masanoriemoto dialysatecalciumalfacalcidolandclinicaloutcomesaposthocanalysisofthejdavidtrial AT katsuhitomori dialysatecalciumalfacalcidolandclinicaloutcomesaposthocanalysisofthejdavidtrial AT tomoakimorioka dialysatecalciumalfacalcidolandclinicaloutcomesaposthocanalysisofthejdavidtrial AT shinyanakatani dialysatecalciumalfacalcidolandclinicaloutcomesaposthocanalysisofthejdavidtrial AT ayumishintani dialysatecalciumalfacalcidolandclinicaloutcomesaposthocanalysisofthejdavidtrial |